JSCO2022 ”Frontier”

TOP > JSCO2022 ”Frontier”

Registration for JSCO "Frontier" on-line viewing only.
Registration deadline
-Noon December 16(JST) for on-demand viewing
*URL/ID for on-demand viewing will be sent individually after registration.
JSCO2022 "Frontier" 1
GI Colorectal Cancer
Oct 20 (Thu.) 16:20~18:00 Room 2 (Ohwada A, Portopia Hotel South Bldg. 1F)
Moderator:
Akihito Tsuji (Medical oncology, Faculty of Medicine, Kagawa University)
Eiji Oki (Surgery and Science, Graduate School, Kyushu University)
Discussant:
Ruihua Xu (Sun Yat-sen University Cancer Center, China)
SSY3-1-1
 -Not included in on-demand streaming
The subgroup analysis of tumor response by BRAF status in modified (m)-FOLFOXIRI plus cetuximab vs. bevacizumab for RAS wild-type metastatic colorectal cancer (mCRC): the DEEPER trial (JACCRO CC-13)
Speaker: Mitsuyoshi Tei
(Department of Surgery, Osaka Rosai Hospital)
SSY3-1-2
Results of an open-label, safety lead-in cohort of Japanese patients in FRESCO-2: A global phase 3 clinical trial evaluating fruquintinib in patients with refractory metastatic colorectal cancer (mCRC)
Speaker: Daisuke Kotani
(National Cancer Center Hospital East)
SSY3-1-3
Molecular residual disease may be a strong predictor for recurrence in rectal cancer with upfront surgery: result from the observational GALAXY study in CIRCULATE-Japan project
Speaker: Koji Ando
(Department of Colorectal Cancer Surgery, National Cancer Center Hospital East)
Discussant:
Takeshi Yamada (Department of Digestive Surgery, Nippon Medical School)
SSY3-1-4
Impact of R0 resection (R0) on overall survival (OS) in metastatic colorectal cancer (mCRC) treated with first-line mFOLFOX6 plus panitumumab (PAN) or bevacizumab (BEV): results from PARADIGM
Speaker: Jun Watanabe
(Gastroenterological Center, Yokohama City University Medical Center)
SSY3-1-5
Impact of left colic artery preservation on bowel perfusion and anastomotic leakage in minimally invasive rectal cancer surgery: results from EssentiAL study
Speaker: Masataka Ikeda
(Division of Lower GI, Department of Gastroenterological Surgey, Hyogo Medical University)
JSCO2022 "Frontier" 2
Gynecological Cancer
Oct 21 (Fri.) 15:30~16:30 Room 2 (Ohwada A, Portopia Hotel South Bldg. 1F)
Moderator:
Koji Matsumoto (Division of Medical Oncology, Hyogo Cancer Center)
Discussant:
Mayu Yunokawa (The Department of gynecology Oncology,
The Cancer Institute Hospital)
SSY3-2-1
Phase 3 EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial of cemiplimab (CEMI) in recurrent or metastatic (R/M) cervical cancer: Subgroup analysis of patients (pts) enrolled in Japan
Speaker: Kosei Hasegawa
(Department of Gynecologic Oncology, International Medical Center, Saitama Medical niversity)
SSY3-2-2
Pembrolizumab Plus Chemotherapy With/Without Bevacizumab in East Asian Patients with Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analysis From the Phase 3 KEYNOTE-826 Study
Speaker: Shin Nishio
(Department of Obstetrics and Gynecology, Kurume University School of Medicine)
SSY3-2-3
Efficacy and safety of trastuzumab deruxtecan in HER2-expressing uterine carcinosarcoma; Multicenter phase II investigator-initiated trial (STATICE TRIAL, NCCH1615)
Speaker: Tadaaki Nishikawa
(Department of Medical Oncology, National Cancer Center Hospital)
JSCO2022 "Frontier" 3
Multi-omics
Oct 21 (Fri.) 16:30~17:30 Room 2 (Ohwada A, Portopia Hotel South Bldg. 1F)
Moderator:
Yoichi Naito (National Cancer Center Hospital East)
Discussant:
Katsuya Tsuchihara (Division of Translational Informatics,
Exploratory Oncology Research and Clinical Trial Center,
National Cancer Center)
SSY3-3-1
 -Not included in on-demand streaming
Gut microbiome associated with BRCA1/2 mutation and response to PARP inhibitor in ovarian cancer: SCRUM-Japan MONSTAR-SCREEN
Speaker: Mika Sakai
(Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center)
SSY3-3-2
 -Not included in on-demand streaming
Gut microbiome comparison between metastatic breast cancer and other cancers, and its association with subtype and efficacy of immune checkpoint inhibitors
Speaker: Hiroyuki Yasojima
(Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital)
SSY3-3-3
Feasibility and Potential Clinical Utility of Multi-omics Analysis for Advanced Solid Tumors: Preliminary Results of the SCRUM-Japan MONSTAR-SCREEN-2
Speaker: Takao Fujisawa
(Translational Research Support Office, National Cancer Center Hospital East)
JSCO2022 "Frontier" 4
GI Non-colorectal Cancer, Head & Neck Cancer
Oct 22 (Sat.) 8:00~9:00 Room 2 (Ohwada A, Portopia Hotel South Bldg. 1F)
Moderator:
Yoshiaki Nakamura (National Cancer Center Hospital East)
Discussant:
Hideaki Bando (Department of Gastroenterology and
Gastrointestinal Oncology, National Cancer Center hospital East)
SSY3-4-1
Nivolumab + chemotherapy or ipilimumab vs chemotherapy as first-line advanced esophageal squamous cell carcinoma treatment: expanded efficacy and safety analyses from CheckMate 648 Japanese subgroup
Speaker: Ken Kato
(National Cancer Center Hospital)
SSY3-4-2
First-line nivolumab plus chemotherapy vs chemotherapy for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: survival analyses by tumor response from CheckMate 649
Speaker: Kensei Yamaguchi
(The Cancer Institute Hospital of JFCR)
SSY3-4-3
Biomarker Analysis with Next Generation Sequencing (NGS) in YATAGARASU, the Phase 2 Study of Apalutamide (APA) plus Goserelin (GOS) for Androgen Receptor (AR)-expressing Salivary Gland Carcinoma (SGC)
Speaker: Yoshitaka Honma
(Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital)
JSCO2022 "Frontier" 5
Genitourinary Cancer
Oct 22 (Sat.) 9:00~10:00 Room 2 (Ohwada A, Portopia Hotel South Bldg. 1F)
Moderator:
Masatoshi Eto (Department of Urology, Graduate School of Medical
Sciences, Kyushu University)
Discussant:
Kazutoshi Fujita (Kindai University)
SSY3-5-1
Efficacy and safety of adjuvant pembrolizumab versus placebo for patients with clear cell renal cell carcinoma at increased risk of recurrence after nephrectomy in the KEYNOTE-564 East Asian subgroup
Speaker: Hiroshi Kitamura
(University of Toyama)
SSY3-5-2
Time course and incidence of common adverse events in patients with metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial
Speaker: Bertrand Tombal
(Cliniques Universitaires Saint Luc, UCLouvain, Belgium)
SSY3-5-3
The comprehensive analysis of gut microbiome and clinical outcomes in patients with metastatic castration-sensitive and -resistant prostate cancer
Speaker: Nobuaki Matsubara
(National Cancer Center East)